Ozuriftamab vedotin

Antibody–drug conjugate

Also known as BA3021

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Also in development:Non-Small Cell Lung Cancer · Phase 1/2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Head and Neck Squamous Cell Carcinoma
Phase 1/2 (1)
Head and Neck Squamous Cell Carcinoma

Competitive landscape

This drug's own stage for Head and Neck Squamous Cell Carcinoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ozuriftamab Vedotin: this drugPhase 2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
CetuximabApprovedMonoclonal antibodyEGFRPartial signal
NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048).
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
NBTXR3Phase 3NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OrdastobartPhase 2/3Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
PepinemabPhase 1/2Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.